Related Policies
• Autologous Platelet-Rich Plasma
• Spinal Fusion
• Ultrasound Bone Growth Stimulation
Policy
Use of recombinant human bone morphogenetic protein-2 (rhBMP-2, InFUSE) may be considered medically necessary in skeletally mature patients for any of the following:
• For anterior lumbar interbody fusion procedures when use of autograft is unfeasible.
• For instrumented posterolateral intertransverse spinal fusion procedures when use of autograft is unfeasible.
• For the treatment of acute, open fracture of the tibial shaft, when use of autograft is unfeasible.
Use of recombinant human bone morphogenetic protein-7 (rhBMP-7, OP-1) may be considered medically necessary in skeletally mature patients for either of the following:
• As an alternative to autograft in compromised patients (e.g., osteoporosis, tobacco use, or diabetes) requiring noninstrumented revision posterolateral intertransverse lumbar spinal fusion, for whom autologous bone and bone marrow harvest are not feasible or are not expected to promote fusion.*
• For recalcitrant long-bone nonunions where use of autograft is unfeasible and alternative conservative treatments have failed.* Bone morphogenetic protein (rhBMP-2 or rhBMP-7) is considered not medically necessary for all other indications, including but not limited to spinal fusion when use of autograft is feasible.
*FDA approved under a Humanitarian Device Exemption (HDE). OP-1 is no longer sold in the United States.
Policy Guidelines
Use of iliac crest bone graft (ICBG) may be considered unfeasible due to situations that may include, but are not limited to, prior harvesting of ICBG or need for a greater quantity of ICBG than available (e.g., for multilevel fusion).
There is not a consensus for the definition of nonunions. One proposed definition is failure of progression of fracture healing for at least 3 consecutive months (and at least 6 months following the fracture) accompanied by clinical symptoms of delayed/nonunion (pain, difficulty weight bearing). (1) The following patient selection criteria are described in the treatment of nonunions:
• At least 3 months have passed since the date of the fracture, AND
• serial radiographs have confirmed that no progressive signs of healing have occurred, AND
• the fracture gap is 1 cm or less, AND
• the patient can be adequately immobilized and is of an age when he/she is likely to comply with non-weight bearing.
A recalcitrant nonunion would thus be considered to be a nonunion with a larger fracture gap (e.g., > than 1 cm) or a nonunion that has persisted for a longer duration of time with no response to conservative treatment (e.g., 3 months of ultrasound or electrical stimulation).
There is no specific CPT or HCPCS code for bone morphogenetic protein. In 2011, CPT code 20930 was revised to include BMP-type materials used in spine surgery:
• 20930: Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure).
In the setting of spinal fusion, bone morphogenetic proteins may be used primarily as an alternative to autologous bone grafting. Since harvesting of autologous bone graft is coded separately from the fusion procedure (i.e., CPT codes 20936-20938), when bone morphogenetic protein is used as an alternative to the bone graft, these codes should no longer be reported. In contrast, the CPT code for treating tibial fracture nonunions with autograft (i.e., CPT code 27724) includes the harvesting component, and, therefore, when bone morphogenetic protein is used as an alternative in this setting, presumably the associated physician's work would be decreased, since no autologous harvest is required. Finally, for treatment of acute, open tibial fractures, bone morphogenetic protein is not used as an alternative to autologous bone graft, but in addition to standard treatment with an intramedullary nail.
ICD-9 procedure code 84.52 explicitly identifies the use of bone morphogenetic protein:
• 84.52: Insertion of recombinant bone morphogenetic protein rhBMP (via collagen sponge, coral, ceramic, or other carriers)
This ICD-9 code notes that the code 84.52 should be used in conjunction with the primary procedure performed:
• 
Benefit Application
Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or noncoverage of these services as it applies to an individual member. Posterior approaches (PLIF and TLIF) allow decompression (via laminotomies and facetectomies) for treatment of spinal canal pathology (e.g., spinal stenosis, lateral recess and foraminal stenosis, synovial cysts, hypertrophic ligamentum flavum) along with stabilization of the spine and are differentiated from instrumented or noninstrumented PLF, which involves the transverse processes. Due to the proximity of these procedures to the spinal canal, risks associated with ectopic bone formation are increased (e.g., radiculopathies). Increased risk of bone resorption around rhBMP grafts, heterotopic bone formation, epidural cyst formation, and seromas has also been postulated.
Regulatory Status
At the present time, two rhBMPs and associated carrier/delivery systems have received approval from the U.S. Food and Drug Administration (FDA). The InFUSE® system consists of rhBMP-2 on an absorbable collagen sponge carrier. The labeled indications for these devices are summarized here. OP-1® consists of rhBMP-7 and bovine collagen, which is reconstituted with saline to form a paste. The addition of carboxymethylcellulose forms putty.
1. InFUSE Bone Graft in conjunction with 1 of 2 interbody fusion devices, i.e., either the LTCage Lumbar Tapered Fusion Device or the Inter Fix RP Threaded Fusion device received FDA approval through the premarket approval (PMA) process:
• The device is indicated for spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at 1 level from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history, function deficit, and/or neurologic deficit and radiographic studies. 2. OP-1 (Stryker Biotech, Hopkinton, MA) has received 2 FDA approvals through the Humanitarian Device Exemption (HDE) process. HDE is available to devices intended for fewer than 4,000 patients per year; as part of this process, the manufacturer is not required to demonstrate unequivocal benefit but only "probable" benefit. OP-1 received the following labeled indications: Both OP-1 and InFUSE Bone Graft/LT-Cage Lumbar Tapered Fusion device are contraindicated in patients who are pregnant, may be allergic to any of the materials contained in the devices, have an infection near the area of the surgical incision, have had a tumor removed from the area of the implantation site or currently have a tumor in that area, or who are skeletally immature.
In July 2008, the FDA issued a public health notification regarding life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. The FDA has received reports of complications with the use of rhBMP in cervical spine fusion.(2) These complications were associated with swelling of neck and throat tissue, which resulted in compression of the airway and/or neurologic structures in the neck. Some reports describe difficulty swallowing, breathing, or speaking. Severe dysphagia following cervical spine fusion using rhBMP products has also been reported in the literature. As stated in the public health notification, the safety and effectiveness of rhBMP in the cervical spine have not been demonstrated, and these products are not approved by the FDA for this use.
In 2011, Medtronic received a "nonapprovable letter" from the FDA for AMPLIFY. The AMPLIFY rhBMP-2 Matrix utilizes a higher dose of rhBMP (2.0 mg/mL) with a compressionresistant carrier and is being evaluated for posterolateral fusion of single-level lumbar (L2-S1) degenerative disc disease.
The U.S. Food and Drug Administration's (FDA) humanitarian device exemptions (HDE) for rhBMP-7 state that use is restricted to patients in whom autologous bone and bone marrow harvest are not feasible or are not expected to promote to promote fusion. Therefore, the policy on rhBMP-7 remains unchanged. As of 2014, rhBMP-7 is no longer marketed in the United States.
Literature Review
In 2013, randomized clinical trials supported the use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in the treatment of anterior interbody spinal fusion when used in conjunction with a tapered cage and also in the treatment of open tibial fractures. (3) In addition, a randomized study supported the use of rhBMP-7 in the treatment of recalcitrant nonunions of the long bones.(4) It should be noted that the majority of trials were designed to show that use of rhBMP is equivalent (not superior) to autologous bone grafting. Although the proposed advantage of rhBMP is the elimination of a separate incision site required for harvesting of autologous bone graft and the associated pain and morbidity secondary to this procedure, a 2011 study by Howard et al. raises questions about the magnitude of pain observed with iliac crest bone graft (ICBG) harvesting.(5) In this study, 112 patients who had an instrumented posterolateral lumbar fusion at 1 or 2 levels were seen at a tertiary spine center for a routine postoperative visit. ICBG was harvested in 53 patients (47.3%) through the midline incision used for lumbar fusion and rhBMP-2 was used in 59 patients (52.7%) with no graft harvest. An independent investigator who was not directly involved in the care of the patient and was unaware of the type of bone graft used in the fusion examined the patient for tenderness over the surgical site, as well as the left and right posterior iliac crest. At a mean follow-up of 41 months (range, 6-211 months), there was no significant difference between the groups in the proportion of patients complaining of tenderness over either iliac crest (3.8 vs 3.6 on a 10-point scale). While 54% of patients complained of tenderness over one or both iliac crests, only 10 patients (9% of 112) had pain over the same crest from which the graft was harvested (mean pain score of 4.4).
Spinal Fusion
In 2013, 2 systematic reviews on the effectiveness and harms of recombinant human bone morphogenetic protein-2 (rhBMP-2) in spine fusion were published.(6,7) These 2 systematic reviews of patient-level data followed a 2011 U.S. The review also found a small improvement in back pain (1 point on a 20-point scale) and Short Form-36 physical component score (PCS, 1.9 percentage points). There was no significant difference between the groups for leg pain. There was a potential for bias in the pain and functional outcomes since outcomes were patient-reported and patients were not blinded to the treatment received. Overall, the increase in successful fusion at up to 24 months did not appear to be associated with a clinically significant reduction in pain.
The meta-analysis by Fu et al. included individual-patient data from 13 RCTs (n=1981) and 31 cohort studies. (7) The review found moderate evidence of no consistent differences between rhBMP-2 and ICBG in overall success, fusion rates, or other effectiveness measures for anterior lumbar interbody fusion (ALIF) or posterolateral fusion (PLF). A small RCT and 3 cohort studies revealed no difference in effectiveness outcomes between rhBMP and ICBG for anterior cervical fusion. Reporting in the original published trials was found to be biased, with journal publications selecting analyses and results that favored rhBMP over ICBG.
Both studies found that cancer risk may be increased with rhBMP-2, although the number of events was low and there was heterogeneity in the types of cancer. Other adverse events were also increased for the BMP group. Simmonds et al. found a higher incidence of early back and leg pain with rhBMP-2 in the analysis of patient-level data The studies consistently reported increased rates of heterotopic bone formation, leg pain/radiculitis, osteolysis and dysphagia, but combined analysis for these outcomes was not performed . The Fu study reported that BMP-2 was associated with a nonsignificantly increased risk for urogenital problems when used for anterior lumbar fusion and an increased risk for wound complications and dysphagia when used for anterior cervical spine fusion. Fu et al. documented that the information on adverse events in the published literature was incomplete in comparison to the total amount of information available.
Off-label use of BMP can include multiple levels and dosages greater than the FDAapproved dose of rhBMP-2 for single-level fusion. In 2013, Carragee et al. assessed cancer risk after high-dose rhBMP-2 (40 mg) using publicly available data from the pivotal, multicenter, randomized controlled trial of AMPLIFY (n=463). (10) The study found an increase in the incidence of cancer, a reduction in the time to first cancer, and a greater number of patients with multiple cancers. For example, at 2 years there were 15 new cancer events in 11 patients in the rhBMP-2 group compared with 2 new cancer events in 2 patients treated with autogenous bone graft, with an incidence rate ratio of 6.75. When calculated in terms of the number of patients with one or more cancer events 2 years after surgery, the incidence rate per 100 person-years was 2.54 in the rhBMP-2 group compared with 0.50 in the control group, and the incidence rate ratio was 5.04. The mean time to development of cancer was 17.5 months after use of rhBMP-2 compared with 31.8 months in the controls. Three patients in the rhBMP-2 group and none in the control group developed multiple new cancers.
Long-Bone Fractures and Nonunions
A 2010 Cochrane review evaluated the effectiveness and costs of rhBMP on fracture healing in acute fractures and nonunions compared with standards of care. (11) The literature was searched to October 2008, and 11 RCTs (976 participants) and 4 economic evaluations were included in the review. The times to fracture healing were comparable between the rhBMP and control groups. There was some evidence for increased healing rates, mainly for open tibial fractures without secondary procedures (RR=1.19). Three trials indicated that fewer secondary procedures were required for acute fractures treated with rhBMP (RR=0.65). The authors concluded that limited evidence suggests that rhBMP may be more effective than standard of care for acute tibial fracture healing; however, the use of rhBMP for treating nonunion remains unclear (RR=1.02).
In 2014, Lyon et al reported a manufacturer-funded randomized double-blind trial of injectable rhBMP-2 in a calcium phosphate matrix for closed tibial diaphyseal fractures. 12 The study had a target enrollment of 600 patients but was stopped after interim analysis with 387 patients enrolled. Addition of the injectable rhBMP-2 paste to the standard of reamed intramedullary nail fixation did not shorten the time to fracture healing, resulting in the study termination due to futility.
Oral and Maxillofacial Procedures
A 2010 AHRQ technology assessment on the state of the evidence of on-label and offlabel use of rhBMP (13) included the following conclusions:
• The strength of the body of evidence on clinical outcomes is moderate that rhBMP-2 does not provide an advantage in prosthesis implantation and functional loading compared to autograft plus allograft bone.
• There is moderate evidence that oral sensory loss associated with autograft bone harvest can be avoided by use of rhBMP-2.
Through April 30, 2011, the FDA's Manufacturer and User Facility Device Experience (MAUDE) received 83 reports of adverse events involving rhBMP-2 in oral and maxillofacial operations. (14) rhBMP-2 was used off-label in 66.3% of these cases and included reconstruction of the mandible after fracture or cancer and alveolar cleft repair. The most frequently reported adverse events were local edema/pain, surgical site infections/wound complications, and graft failure.
Overall, the evidence does not support a health benefit of rhBMP in oral and maxillofacial procedures.
Additional Applications
There has been research interest in the following applications: management of early stages of osteonecrosis of the vascular head, as an adjunct to hip arthroplasty to restore bone defects in the acetabulum or femoral shaft, and as an adjunct to distraction osteogenesis (i.e., Ilizarov procedure). (15, 16) The literature regarding these applications consists of small case series; no controlled trials have been identified.
Ongoing Clinical Trials
A search of online site ClinicalTrials.gov in July 2013 identified several ongoing studies. Of particular interest is an industry-sponsored Phase II randomized controlled dose-finding study of intra-articular BMP-7 for osteoarthritis of the knee (NCT01111045). The study lists an enrollment of 355 subjects and is described as completed as of January 2012. As of October 2014, no publications from this study have been identified.
Summary
In 2013, 2 systematic reviews on recombinant human bone morphogenetic protein-2 (rhBMP-2) that used manufacturer-provided individual patient data were published. Overall, these systematic reviews found little to no benefit of rhBMP-2 over iliac crest bone graft for spinal fusion, with an uncertain risk of harm. The small benefits reported do not support the widespread use of rhBMP-2, but do leave the possibility that rhBMP-2 may lead to clinically significant improvements in selected subgroups, such as patients in whom use of iliac crest bone graft (ICBG) is unfeasible and have a high risk of fusion failure. While there was a low adverse event rate overall, concerns remain about the possibility of increased adverse event rates with rhBMP-2, including cancer. Based on this new evidence, it is not possible to conclude that the small benefits of rhBMP-2 outweigh the risks. Therefore, rhBMP-2 is considered to be not medically necessary when use of ICBG is feasible. In cases where use of ICBG is not feasible, such as when previous bone harvest has been performed, the benefit of rhBMP in promoting fusion will likely outweigh the adverse effects, and therefore rhBMP-2 may be considered medically necessary.
The U.S. Food and Drug Administration's humanitarian device exemptions (HDE) for rhBMP-7 state that use is restricted to patients in whom autologous bone and bone marrow harvest are not feasible or are not expected to promote to promote fusion. Therefore, the policy on rhBMP-7 remains unchanged. As of 2014, rhBMP-7 is no longer marketed in the United States.
Use of rhBMP has not been shown to be as beneficial as the established alternative (ICBG) and evidence is insufficient to permit conclusions concerning the effect of rhBMP for other indications, including but not limited to:
• Cervical spinal fusion • Posterior or transforaminal lumbar interbody spinal fusion (this is considered investigational because of safety concerns related to ectopic bone formation in the spinal canal); • Treatment of noninstrumented posterolateral intertransverse spinal fusion when autograft is feasible and expected to promote fusion; • As an alternative or adjunct to bone grafting in other locations, including craniomaxillofacial surgeries.
Practice Guidelines and Position Statements
Guidelines on lumbar spinal fusion from the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons were updated in 2014. (17) AANS/CNS gave a Grade B recommendation (multiple level II studies) for the use of rhBMP-2 as a substitute for autologous iliac crest bone for anterior lumbar interbody fusion and single-level posterolateral instrumented fusion. Grade C recommendations were made for rhBMP-2 as an option for PLIF and TLIF , posterolateral fusion in patients older than 60 years, and as a graft extender for either instrumented or noninstrumented posterolateral fusions. AANS/CNS also gave a Grade C recommendation (based on multiple level IV and V studies) that the use of rhBMP-2 as a graft option has been associated with a unique constellation of complications of which the surgeon should be aware when considering the use of this graft extender/substitute.
U.S. Preventive Services Task Force Recommendations
The U.S. Preventive Services Task Force has not addressed the use of bone morphogenetic protein. None identified.
Medicare National Coverage
The Centers for Medicare and Medicaid Services (CMS) has established an add-on to the diagnosis-related group (DRG) payment to cover a portion of the cost of new technologies during the 2-year period before charge data for the technologies are incorporated into the DRG weights. To qualify, a technology must be new, must provide verifiable improvement in the treatment or diagnosis of beneficiaries, and the mean standardized charge for treatment using the new technology must be at least 1 standard deviation above the mean standardized charge for treating the same case without the new technology. 
MN/NMN
The following services may be considered medically necessary when policy criteria are met. Services are considered not medically necessary when policy criteria are not met. 
Definitions of Decision Determinations
Medically Necessary: A treatment, procedure or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.
Investigational/Experimental: A treatment, procedure or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but
has not yet been granted.
Split Evaluation: Blue Shield of California / Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a Split Evaluation, where a treatment, procedure or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.
